Engineered RNA Modification Recognition

摘要 Alida Biosciences Inc正在开发一种用于分析表转录组的商业平台， 天然应用于RNA以调节RNA生物学的所有方面的化学修饰的总和： 转录（mods是共转录安装的），翻译，转录生命周期，贩运，替代 剪接，RNA折叠，RNA-蛋白质相互作用等等。表观转录组学领域发展迅速， 由于这种生物学的重要性以及利用RNA修饰作为 诊断生物标志物和干预表转录组途径作为一个有前途的新的范例，在药物 特别是在癌症化疗中。Alida的平台技术将使epitranscriptomics更加 通过提供用户友好的工作流程、集成的过程控制和基于云的数据处理， 生物信息学在这项SBIR资助中，我们寻求开发工程化的RNA修饰结合剂， 融入我们的平台。新试剂的增强性能将专门针对我们的 平台，以最大限度地提高灵敏度和选择性，这是特别重要的高价值的临床样品， 只有纳克数量的RNA可能是可用的：针活检，FFPE样本，和 他人

Abstract Alida Biosciences Inc is developing a commercial platform for the analysis of the epitranscriptome, which is the totality of chemical modifications applied naturally to RNA to regulate possibly all aspects of RNA biology: transcription (mods are installed co-transcriptionally), translation, transcript lifetime, trafficking, alternative splicing, RNA folding, RNA–protein interactions, and more. The field of epitranscriptomics has seen rapid growth, motivated by the significance of this biology and the emerging opportunities to use RNA modifications as diagnostic biomarkers and to intervene in epitranscriptomic pathways as a promising novel paradigm in drug development, especially in cancer chemotherapy. Alida’s platform technology will make epitranscriptomics more accessible by offering a user-friendly workflow, integrated process controls, and cloud-based data handling and bioinformatics. In this SBIR grant, we seek to develop engineered RNA modification binding agents for integration into our platform. The enhanced properties of the novel agents will be optimized specifically for our platform to maximize sensitivity and selectivity, which is especially significant for high-value clinical samples in which only sub-nanogram quantities of RNA are likely to be available: needle biopsies, FFPE samples, and others.